EP0906123A4 - OLIGONUCLEOTIDES CIBLES SUR L'ARNm DE L'ANGIOTENSINOGENE - Google Patents
OLIGONUCLEOTIDES CIBLES SUR L'ARNm DE L'ANGIOTENSINOGENEInfo
- Publication number
- EP0906123A4 EP0906123A4 EP97916760A EP97916760A EP0906123A4 EP 0906123 A4 EP0906123 A4 EP 0906123A4 EP 97916760 A EP97916760 A EP 97916760A EP 97916760 A EP97916760 A EP 97916760A EP 0906123 A4 EP0906123 A4 EP 0906123A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- oligonucleotides targeted
- angiotensinogen mrna
- angiotensinogen
- mrna
- oligonucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000004881 Angiotensinogen Human genes 0.000 title 1
- 108090001067 Angiotensinogen Proteins 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/311—Phosphotriesters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3511—Conjugate intercalating or cleaving agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61686096A | 1996-03-15 | 1996-03-15 | |
| PCT/US1997/004019 WO1997033623A1 (fr) | 1996-03-15 | 1997-03-14 | OLIGONUCLEOTIDES CIBLES SUR L'ARNm DE L'ANGIOTENSINOGENE |
| US616860 | 2000-07-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0906123A1 EP0906123A1 (fr) | 1999-04-07 |
| EP0906123A4 true EP0906123A4 (fr) | 1999-05-26 |
Family
ID=24471266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97916760A Withdrawn EP0906123A4 (fr) | 1996-03-15 | 1997-03-14 | OLIGONUCLEOTIDES CIBLES SUR L'ARNm DE L'ANGIOTENSINOGENE |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0906123A4 (fr) |
| JP (1) | JP2000506866A (fr) |
| AU (1) | AU2529697A (fr) |
| CA (1) | CA2248932A1 (fr) |
| WO (1) | WO1997033623A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999015643A2 (fr) * | 1997-09-25 | 1999-04-01 | University Of Florida | COMPOSITIONS OLIGONUCLEOTIDIQUES ANTISENSE CIBLEES SUR L'ARNm DE L'ENZYME DE CONVERSION DE L'ANGIOTENSINE ET METHODES D'UTILISATION |
| WO2014018930A1 (fr) | 2012-07-27 | 2014-01-30 | Isis Pharmaceuticals. Inc. | Modulation de maladies associées au système rénine—angiotensine (ras) par l'angiotensinogène |
| EP2986599A1 (fr) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires |
| CN113817735A (zh) | 2015-10-08 | 2021-12-21 | Ionis制药公司 | 用于调节血管紧张素原表达的化合物和方法 |
| LT4136092T (lt) | 2020-11-18 | 2024-09-25 | Ionis Pharmaceuticals, Inc. | Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui |
| CN120775847A (zh) * | 2021-10-20 | 2025-10-14 | 厦门甘宝利生物医药有限公司 | Agt抑制剂及其用途 |
| IL312811A (en) | 2021-11-16 | 2024-07-01 | Shanghai Argo Biopharmaceutical Co Ltd | Composition and method for inhibiting angiotensinogen (agt) protein expression |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995030330A1 (fr) * | 1994-05-10 | 1995-11-16 | Dzau Victor J | Procede pour l'administration in vivo d'agents therapeutiques par des liposomes |
-
1997
- 1997-03-14 EP EP97916760A patent/EP0906123A4/fr not_active Withdrawn
- 1997-03-14 AU AU25296/97A patent/AU2529697A/en not_active Abandoned
- 1997-03-14 JP JP9532856A patent/JP2000506866A/ja active Pending
- 1997-03-14 WO PCT/US1997/004019 patent/WO1997033623A1/fr not_active Ceased
- 1997-03-14 CA CA002248932A patent/CA2248932A1/fr not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995030330A1 (fr) * | 1994-05-10 | 1995-11-16 | Dzau Victor J | Procede pour l'administration in vivo d'agents therapeutiques par des liposomes |
Non-Patent Citations (7)
| Title |
|---|
| COOK, J. ET AL.: "Identification and antisense inhibition of a renin-angiotensin system in transgenic cardiomyocytes", AM. J. PHYSIOL. (1995), 268(4, PT. 2), H1471-H1482, XP002098211 * |
| PHILLIPS, I. ET AL.: "Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes.", KIDNEY INT., vol. 46, 1994, pages 1554 - 1556, XP002098212 * |
| PHILLIPS, I.: "Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension", HYPERTENSION, vol. 29, January 1997 (1997-01-01), pages 177 - 187, XP002098214 * |
| See also references of WO9733623A1 * |
| UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE", CHEMICAL REVIEWS, vol. 90, no. 4, 1 June 1990 (1990-06-01), pages 543 - 584, XP000141412 * |
| WIELBO, D. ET AL.: "Antisense inhibition of hypertension in the spontaneously hypertensive rat", HYPERTENSION, vol. 25, 1995, pages 314 - 319, XP002098210 * |
| WIELBO, D. ET AL.: "Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides", HYPERTENSION, vol. 28, July 1996 (1996-07-01), pages 147 - 151, XP002098213 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997033623A1 (fr) | 1997-09-18 |
| CA2248932A1 (fr) | 1997-09-18 |
| AU2529697A (en) | 1997-10-01 |
| EP0906123A1 (fr) | 1999-04-07 |
| JP2000506866A (ja) | 2000-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB9620749D0 (en) | Identifying antisense oligonucleotides | |
| SG74615A1 (en) | Photocrosslinkable polymers | |
| ZA98376B (en) | Sulfamide-metalloprotease inhibitors | |
| IL149694A0 (en) | Therapeutic uses of lna-modified oligonucleotides | |
| GB9510718D0 (en) | Antisense oligonucleotides | |
| GB2321641B (en) | Sulfamide-metalloprotease inhibitors | |
| HUP0300627A3 (en) | Therapeutically useful synthetic oligonucleotides | |
| AU5259498A (en) | Antisense oligonucleotides | |
| GB9505438D0 (en) | Antisense oligonucleotides | |
| ZA975742B (en) | Modified oligonucleotides. | |
| GB2339855B (en) | Distributor | |
| TW418650U (en) | Mat | |
| EP0972830A4 (fr) | Genes associes au cancer | |
| GB9719727D0 (en) | New plant genes | |
| GB9711919D0 (en) | Oligonucleotide derivatives | |
| EP0906123A4 (fr) | OLIGONUCLEOTIDES CIBLES SUR L'ARNm DE L'ANGIOTENSINOGENE | |
| DE69833112D1 (en) | Rna polymerase | |
| GB2348002B (en) | Microarrayer | |
| MA23595A1 (fr) | Oligonucleotides antisense | |
| GB0128204D0 (en) | Ground treatment | |
| GB9711167D0 (en) | Telomere-associated chromosome fragmentation | |
| GB9810827D0 (en) | Sanitising methods | |
| GB9825687D0 (en) | Oligonucleotide conjugation | |
| CA2180077A1 (fr) | Inhibiteurs de l'arn-polymerase | |
| PL331278A1 (en) | Distributor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19980929 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| AX | Request for extension of the european patent |
Free format text: AL PAYMENT 980929;LT PAYMENT 980929;LV PAYMENT 980929;RO PAYMENT 980929;SI PAYMENT 980929 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19990413 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19990625 |